N-Acetylcysteine (NAC) in Primary Sclerosing Cholangitis (PSC)
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 15 people, planned
- Starts
- 5 Dec 2026
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional
- Treatments tested
- N-Acetylcysteine (NAC) Treatment
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Other criteria
- **Inclusion Criteria:**
- Adults aged 18 to 70 years
- Diagnosis of primary sclerosing cholangitis (PSC) for at least 6 months, confirmed by characteristic cholangiographic findings, without evidence of secondary sclerosing cholangitis
- Serum alkaline phosphatase (ALP) greater than 1.33 times the upper limit of normal at screening
- Platelet count greater than 150,000/mm³, serum albumin greater than 3.3 g/dL, and serum creatinine below the upper limit of normal
- For participants receiving ursodeoxycholic acid (UDCA), a stable dose for at least 3 months before screening. Participants not receiving UDCA must have been off UDCA for at least 3 months
- For participants receiving mesalamine, sulfasalazine, immunomodulators, or biologic medications for inflammatory bowel disease, a stable dose for at least 4-8 weeks before enrollment, with no planned treatment changes during the study
- For participants receiving oral corticosteroids, a daily dose not exceeding 20 mg of prednisone or 6 mg of budesonide at enrollment
- Willingness and ability to provide informed consent and comply with study visits, medication administration, and laboratory testing
- No concurrent enrollment in another interventional PSC trial; **Exclusion Criteria:**
- Pregnancy or breastfeeding
- Known hypersensitivity to N-acetylcysteine (NAC) or any component of the study capsules
- Alanine aminotransferase (ALT) greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal (except in participants with Gilbert syndrome), or international normalized ratio (INR) greater than 1.2
- Decompensated cirrhosis, including ascites, hepatic encephalopathy, or variceal bleeding
- Small-duct primary sclerosing cholangitis
- Other causes of liver disease, including secondary sclerosing cholangitis, viral liver disease, alcohol-related liver disease, or other autoimmune liver diseases, including positive antimitochondrial antibodies. Participants with nonalcoholic fatty liver disease may be eligible if there is no evidence of nonalcoholic steatohepatitis
- History of liver transplantation, hepatocellular carcinoma, or cholangiocarcinoma
- Ascending cholangitis within 90 days before enrollment
- Severe ulcerative colitis flare requiring intravenous corticosteroids within 3 weeks before enrollment, or an anticipated change to a new inflammatory bowel disease medication within 3 months
- Concurrent participation in another therapeutic clinical trial
- Any laboratory abnormality or medical condition that, in the investigator's judgment, could compromise participant safety or interfere with the evaluation of study outcomes
- Current regular use of an NAC-containing supplement outside the study
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Omid yazdani, MDNot yet recruiting
About the trial
What the trial wants to find out
Primary sclerosing cholangitis (PSC) is a chronic disease that causes inflammation and scarring of the bile ducts and can lead to progressive liver damage. There are currently no approved medications that have been shown to improve long-term outcomes in patients with PSC.
Read full original descriptionShow less
The purpose of this pilot study is to evaluate whether N-acetylcysteine (NAC), a medication that helps the body produce an antioxidant called glutathione, may improve liver blood tests in people with PSC.
This is a single-center, open-label study involving approximately 15 adults with PSC. All participants will receive oral NAC at a dose of 1,200 mg per day for the first 12 weeks. At Week 12, the dose will either remain the same or increase to 1,800 mg per day, depending on changes in a liver blood test called alkaline phosphatase (ALP).
Participants will continue treatment through Week 16. Those with a substantial improvement in ALP may be eligible to continue treatment through Week 20.
Researchers will evaluate changes in liver blood tests, treatment safety, side effects, and medication adherence. Additional blood tests may help researchers better understand how NAC affects liver injury.
This study is intended to provide preliminary information about the potential benefits and safety of NAC in PSC. It is not designed to establish whether NAC is an effective treatment for PSC.
The group in the trial
- N-Acetylcysteine (NAC) TreatmentTreatment being tested
Participants will receive oral N-acetylcysteine (NAC) at a dose of 600 mg twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in alkaline phosphatase (ALP) of at least 40% from baseline will continue at 1,200 mg/day, while those with less than a 40% reduction will increase to 1,800 mg/day through Week 16. Participants achieving at least a 50% reduction in ALP at Week 16 may continue treatment through Week 20, according to the study protocol.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Proof-of-Principle Pilot Study of N-Acetylcysteine (NAC) Monotherapy to Assess Biochemical Changes in Primary Sclerosing Cholangitis (PSC)
- Criteria questions
- Built from NCT07939841, who can take part
- Record updated
- 16 November 2026